Volver a Agenda
Session Chair(s)
Suzanne Sensabaugh, MBA, MS
President and Principal Consultant
HartmannWillner LLC, United States
Learning Objective : Define nanotechnology; Explain the application of nanotechnology as it relates to drugs and biologics; Describe the current landscape of medical products in development; Enumerate development, scientific, and regulatory challenges; Identify the preclinical and clinical requirements.
Speaker(s)
Biomedical Nanotechnology: The Smaller the Thing, the Bigger the Challenge
Michael Drues, PHD
Vascular Sciences, United States
Founder and President
Nanomaterials in Drug Products: A Regulatory Update
Celia N. Cruz, PHD
FDA, United States
Senior Product Quality Reviewer, OPS, CDER
Industry Perspectives of Nanomedicines: It's a Small World After All
Frank J Malinoski, MD, PHD
Liquidia Technologies, United States
Chief Medical Officer
¿Tiene una cuenta?